Torrent Pharma to launch Molnupiravir under Molnutor brand name to treat COVID-19

The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir, has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India.

Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration for emergency use authorisation (EUA) for the treatment of COVID-19 in adults. 

Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback’s molnupiravir under the brand name Molnutor in India for the treatment of COVID-19.

Earlier this year, Torrent Pharma inked a non-exclusive voluntary licensing pact with MSD for manufacturing, distribution and marketing of Molnupiravir in more than 100 low-and middle-income markets, including India.

The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir, has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India.

Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration for emergency use authorisation (EUA) for the treatment of COVID-19 in adults. 

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.